Australia's fledgling medicinal cannabis sector has been blazing ahead with research projects in the face of the COVID-19 pandemic and well-known investors are looking for winners.
The nation's cannabis businesses have increasingly been refining their focus over the past year as players look to differentiate themselves amidst a sea of competition, and well known investors are considering strategy and IP protection closely.Last week ASX-listed Zelira Therapeutics, formerly Zelda Therapeutics, scored a new substantial shareholder when billionaire investor Alex Waislitz's Thorney Investment Group upped its stake from 2 per cent to 5.2 per cent.
Incannex is progressing trials for its major research programs and is hopeful of soon being able to show one of its flagship products is effective in protecting the brain against secondary injuries in the days and weeks after a traumatic brain injury or concussion. Aside from concussion treatment, it is looking at applying its cannabinoid products to treat acute respiratory distress and sleep apnoea. Last week the company got approval to launch a sleep trial in partnership with Melbourne's Alfred hospital.
MsEmmaK Legalise